Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscularis propria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Muscularis propria. Displaying page 1 of 1.
    EudraCT Number: 2010-023083-40 Sponsor Protocol Number: SPON830-10 Start Date*: 2012-03-19
    Sponsor Name:Cardiff University
    Full Title: A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse
    Medical condition: Rectal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003496-11 Sponsor Protocol Number: EN3348-303 Start Date*: 2012-02-08
    Sponsor Name:Endo Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects wi...
    Medical condition: BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000331-14 Sponsor Protocol Number: ICORG 05-02/NSABP C-08 Start Date*: 2005-04-08
    Sponsor Name:All Ireland Cooperative Oncology Research Group
    Full Title: A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX -6) every 2 weeks with Bevacizumab to the same regimen without Bevacizumab for the treatme...
    Medical condition: Resected stage II or stage III adenocarcinoma of the colon
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003447-34 Sponsor Protocol Number: REQ-0000020479 Start Date*: 2019-04-03
    Sponsor Name:Hellenic Genitourinary Cancer Group (HGUCG)
    Full Title: Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study
    Medical condition: muscle-invasive bladder cancer (MIBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005782-59 Sponsor Protocol Number: 08/0136 Start Date*: 2010-09-29
    Sponsor Name:University College London
    Full Title: ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000414-41 Sponsor Protocol Number: PROICM2021-01GRE Start Date*: 2021-07-19
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy
    Medical condition: Locally advanced rectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007450 Carcinoma of rectum stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003009-40 Sponsor Protocol Number: CCR4326 Start Date*: 2015-12-18
    Sponsor Name:Royal Marsden NHS Foundation Trust
    Full Title: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good And Poor Responders To Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial
    Medical condition: Rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10061758 Chemotherapy PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    18.0 10042613 - Surgical and medical procedures 10068093 Gastrointestinal surgery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003581-27 Sponsor Protocol Number: CA209-9UT Start Date*: 2020-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Ca...
    Medical condition: BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:29:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA